#biogenidec

Google entra nel campo farmaceutico contro la sclerosi multipla #Google #Biogen

Google ha stretto un accordo con e Biogen Idec per combattere e curare la sclerosi multipla. (more…)

Summary: On Part 1 I posted last week, I stated a number of factors that focused on why HCP’s are so hard to impact and engage these days. Yes there is plethora of means to do so, but there are also many barriers. The main one is they have no time!

This post focuses on the App-mania…the challenges HCP’s face as they try to work with their patients, satisfaction ratings and Outcomes.

Let’s look…

H2H Marketing in Biopharma: A Utopian ideal, naivete or the inevitable and needed conclusion.

So what happens when Biopharma deploys all the digital/multi-channel technology it is investing in? A vessel without a mission is one adrift. Let’s talk H2H.

H2H, in simplest terms, is approaching marketing from a profoundly human, empathetic, authenticity-based common sense approach.

Why is H2H important to know about? Because to ignore it is to court failure of the greatest magnitude and to…

Better outcomes = Managing the Entire Customer Experience. ZMOT, UMOT and the Patient Journey

Change brings out the best, worst and everything in-between in both people and companies (after all, according to Citizens United, companies are people.)

Pharma, health care in general, hospitals, ACO’s, all are now forced to share the same overarching objective: patient outcomes. This shared objective has become the single greatest stimulus for panic, opportunity and innovation I have ever seen.…